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Abstract
Despite the well-documented effects of plasma lipid lowering regimes halting atherosclerosis lesion development and
reducing morbidity and mortality of coronary artery disease and stroke, the transcriptional response in the atherosclerotic
lesion mediating these beneficial effects has not yet been carefully investigated. We performed transcriptional profiling at
10-week intervals in atherosclerosis-prone mice with human-like hypercholesterolemia and a genetic switch to lower
plasma lipoproteins (Ldlr
2/2Apo
100/100 Mttp
flox/flox Mx1-Cre). Atherosclerotic lesions progressed slowly at first, then
expanded rapidly, and plateaued after advanced lesions formed. Analysis of lesion expression profiles indicated that
accumulation of lipid-poor macrophages reached a point that led to the rapid expansion phase with accelerated foam-cell
formation and inflammation, an interpretation supported by lesion histology. Genetic lowering of plasma cholesterol (e.g.,
lipoproteins) at this point all together prevented the formation of advanced plaques and parallel transcriptional profiling of
the atherosclerotic arterial wall identified 37 cholesterol-responsive genes mediating this effect. Validation by siRNA-
inhibition in macrophages incubated with acetylated-LDL revealed a network of eight cholesterol-responsive atherosclerosis
genes regulating cholesterol-ester accumulation. Taken together, we have identified a network of atherosclerosis genes that
in response to plasma cholesterol-lowering prevents the formation of advanced plaques. This network should be of interest
for the development of novel atherosclerosis therapies.
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Introduction
Atherosclerosis is a lifelong, progressive disease that becomes
clinically significant in 50% of the population, leading to
myocardial infarction (MI), stroke, and eventually death. Statin-
based lipid-lowering regimens reduce morbidity and mortality
from both MI and stroke [1]. Aggressive statin regimens can even
cause regression of atherosclerosis [2] but sometimes generate
severe side effects. To fully exploit the beneficial effects of lipid
lowering, we need a better understanding of the transcriptional
changes induced by lowering plasma lipoproteins [3]. Whole-
genome measurement technologies developed in the aftermath of
the human [4,5] and mouse [6] genome projects offer the
opportunity to uncover entire repertoires of changes in gene
expression related to complex diseases like atherosclerosis and
reveal their interplay in regulatory networks. We used the Ldlr
2/
2Apo
100/100Mttp
flox/floxMx1-Cre mouse model [7] that has a plasma
lipoprotein profile similar to that of familial hypercholesterolemia
(Ldlr
2/2Apob
100/100) and a genetic switch to block hepatic synthesis
of lipoproteins and thereby lower plasma lipoproteins (Mttp
flox/
floxMx1-Cre) to investigate the effects of plasma cholesterol-
lowering on atherosclerosis development and to identify choles-
terol-responsive atherosclerosis genes.
Results
Basic Characteristic and Atherosclerotic Lesion
Development
The mice were sacrificed at 10, 20, 30, 40, 50 and 60 weeks of
age. Lesion area and morphological changes were assessed in a
total of 87 Ldlr
2/2Apob
100/100Mttp
flox/floxMx1-Cre mice (Figure 1A–
1C). Only occasional spots of Sudan IV staining were detected at
10 weeks (n=10, not shown), but lesions were detected in all mice
at 20 weeks. Lesion size increased by ,1.6% between weeks 20
and 30 (P=0.05) and by ,7.2% between weeks 30 and 40
(P,0.0001). At 20 weeks, the main morphological feature was
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plaques were detected. At 30 weeks, all mice had small plaques
(red nontransparent areas with distinct boundaries) in the aortic
arch that had expanded markedly at 40 weeks. Thereafter plaque
growth was restrained (Figure 1A and 1B). The area of Oil-red-O
staining in the aortic root followed a similar progression curve as
the Sudan IV lesion staining whereas CD68 staining increased
sharply between week 20 and 30 (Figure 1C). Plasma cholesterol
increased slightly with age whereas plasma triglyceride and glucose
levels were unchanged (Table 1).
Transcriptional Profiling of Lesion Development
Next, we identified transcriptional changes of atherosclerosis
development using 32 cDNA arrays (5 to 7 per time point). Of
19,879 genes (Mouse Genome Informatics Database, www.jax.
org), 1259 (6.3%) were differentially expressed according to
empirical Bayes statistics [8] at one or more time comparisons
(FDR,0.05, n=1259). Of these, 329 (27%) had previously been
related to atherosclerosis (Table S1). Of genes with established
roles in atherosclerosis (Table S6), 78% (88/111) were among the
differentially expressed genes.
Cluster analysis of mRNA levels of differentially expressed genes
(n=1259) generated four distinct clusters (Figure 2A, Table S21).
Cluster 1 genes (n=293, Table S8) were activated during rapid
lesion expansion between 30 and 40 weeks (Figure 1A) and
remained activated at 60 weeks (Figure 2A). This cluster had the
highest percentage (36%) of genes previously related to athero-
sclerosis or atherosclerosis cell types (Figure 2A, Table S1), and
89% of the genes were related to inflammatory cells (Tables S13,
S17, S22).
Gene activities peaked at week 30 in cluster 2 (n=331; Table
S9) and at week 40 in cluster 4 (n=300; Table S11) and were
suppressed at late stages of progression (Figure 2A); 73% had no
previous relation to atherosclerosis or atherosclerosis cell types
(Tables S14, S16, S18, S20, S23, and S25).
Cluster 3 (n=339; Table S10) was particularly interesting
because the mRNA levels of these genes peaked at 30 weeks and
were suppressed at 40 weeks (Figure 2A), coinciding with the rapid
lesion expansion phase. This cluster had fewer atherosclerosis-
related genes than cluster 1 but more than clusters 2 or 4 and
consisted mainly of genes related to carboxylic and lipid
metabolism (Tables S15, S19, and S24). Thirteen of 19 TFs are
well-established in lipid and energy metabolism, including the
peroxisome proliferator activator receptors (PPARs; Ppara (Entrez
Gene ID 19013), Ppard (Entrez Gene ID 19015), and Pparg
(Entrez Gene ID 19016)) and sterol regulatory element binding
factor 2 (Srebf2, Entrez Gene ID 20788), which also have been
implicated in the regulation of foam-cell formation.
Cell-type-specific markers (Table S7) were used to investigate
changes to the relative cell type contents of the lesion over time.
mRNA levels of these markers on the GeneChips indicated that
most of the major lesion cell types (smooth muscle and endothelial
and T-cells) were relatively stable during lesion progression
(Figure 2B). In contrast, macrophages/foam cells increased in
number between 20 and 30 weeks and remained at this level until
60 weeks (Figure 2B). This change in lesion macrophage number
confirmed the notion obtained from the CD68 staining
(Figure 1C).
In summary, the gene expression data suggest that macrophages
gradually accumulate in the early phases of lesion development,
reaching a density at 30 weeks (Figure 2B), inducing an
inflammatory reaction (Figure 2A, cluster 1), increasing lipid
accumulation in foam cells (Figure 2A, cluster 3), and causing
rapid lesion expansion (Figure 1A and 1B). The lipid accumulation
in foam cells was sustained until 40 weeks (Figure 2A, cluster 3).
The inflammation persisted in the later phases (Figure 2A, cluster
1).
This interpretation of the expression data was supported by a
immunohistochemical examination showing that lipid-poor mac-
rophages had accumulated at 30 weeks and then had expanded
and become lipid-rich at 40 weeks (Figure 2C).
Identification of Plasma Cholesterol-Responsive
Atherosclerosis Genes
To investigate the role of plasma cholesterol in causing the
rapid lesion expansion between week 30 and 40, we genetically
lowered plasma LDL cholesterol by inducing recombination of
Mttp (Ldlr
2/2Apob
100/100Mttp
D/D) in 30-week-old mice. Plasma
cholesterol was reduced .80% (427 to 54631 mg/L, n=6) and
remained at this level for 10 weeks until sacrifice. At sacrifice,
lesion size had not increased and was significantly less than in
controls with high cholesterol (Figure 3A). Lesion histology was
indistinguishable from that in 30-week-old mice with high plasma
cholesterol (not shown). Thus, lowering plasma cholesterol at
30 weeks eliminated the formation of advanced plaques observed
in mice with sustained high levels of plasma cholesterol.
To investigate the molecular mechanisms in the atherosclerotic
arterial wall induced by the genetic lowering of plasma cholesterol
preventing the formation of advanced lesion, we performed
additional gene expression profiling of lesion mRNA isolated from
mice sacrificed immediately after plasma cholesterol lowering by
Cre-mediated recombination of Mttp in the liver (Text S1). The
mRNA levels of thirty-seven atherosclerosis genes responded
strongly to the cholesterol lowering (Table S12). To determine if
these changes were true changes in cellular mRNA levels or a
consequence of changes in lesion size or the relative contributions
of cell types, we examined lesion size and the relative numbers of
the four major atherosclerosis cell types. Neither lesion size
(Figure 3B) nor cell type distribution (Figure 3C) was affected by
Author Summary
Atherosclerosis is present in the major arteries of all adults.
In industrial societies, atherosclerosis progression in ,50%
of adults leads to clinical manifestations such as stroke and
myocardial infarction, and eventually death. Lowering
circulating LDL-cholesterol levels can slow atherosclerosis
progression and even cause regression. Yet, little is known
about the genes in the atherosclerotic arterial wall that
mediate those effects. To identify such genes, we studied
genetically modified mice in which high levels of human-
like LDL-cholesterol cause rapid progression of atheroscle-
rosis; the mice also had a genetic ‘‘switch’’ to lower LDL-
cholesterol. Lowering LDL-cholesterol at a critical point
before advanced plaques developed stopped lesion
progression. Analysis of gene expression in response to
the lowering of plasma LDL-cholesterol revealed 37 lesion
genes as possible mediators of this effect. We validated
some of these genes in macrophages using siRNA
incubated with acetylated-LDL to mimic foam cells, which
are central to atherosclerosis progression. ‘‘Reverse engi-
neering’’ of whole-genome expression data from these
experiments revealed a regulatory gene network of
cholesterol-responsive atherosclerosis genes that control
foam cell formation. This network and the individual genes
within it merit further attention as targets for drugs to
prevent the transformation of early harmless lesions into
advanced, clinically significant plaques.
Cholesterol-Responsive Genes in Atherogenesis
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Figure 1. Atherosclerosis progression in Ldlr
2/2Apob
100/100 Mttp
flox/flox mice. (A) Box plots of atherosclerosis progression at 20 (n=12), 30
(n=25), 40 (n=15), 50 (n=15), and 60 weeks (n=10). P,0.05, 20 vs. 30 weeks; P,0.0001, 30 vs. 40 weeks; P,0.02, 40 vs. 50 weeks. Values are surface
lesion areas assessed by Sudan IV staining of pinned-out aortas and given as a percentage of the surface of the entire aorta. Boxes enclose values
between the 75
th and 25
th percentiles, bars indicate values between the 90
th and 10
th percentiles, and black dots indicate individual observations
outside these boundaries. (B) Representative aortic trees (above) and arches (below). (C) Representative sections of the aortic root were stained with
Oil-red-O and counterstained with hematoxylin (Htx) or show CD68 fluorescence and counterstained with DAPI.
doi:10.1371/journal.pgen.1000036.g001
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surface markers (Table S7), Oil-red-O staining, and immunohis-
tochemical analysis of CD68 expression (Figure 3D) suggesting
that the observed changes in mRNA levels were true gene activity
changes in response to the plasma cholesterol lowering.
Although the recombination of Mttp in the Ldlr
2/2Apob
100/
100Mttp
flox/floxMx1-Cre mouse leading to lowering of plasma
cholesterol mainly takes place in the liver, the intraperitoneal
pI—pC treatment and the following activation of Cre-recombi-
nase may theoretically in themselves affect gene expression in the
atherosclerotic arterial wall. To investigate this possibility, we bred
control mice lacking the floxed Mttp allele (Ldlr
2/2Apob
100/
100Mttp
wt/wtMx1-Cre) and treated these mice with pI-pC (n=4)
and PBS (n=5). As expected, the pI-pC treatment had no effect
on plasma cholesterol levels (not shown). Moreover, GeneChip
analysis of aortic arch mRNA samples from these mice (n=4+5)
showed a low number of differentially expressed genes and none of
these were the 37 cholesterol-responsive genes.
Regulatory Network Identification of Cholesterol
Responsive Macrophage Genes
The rapid expansion of the lesions between weeks 30 and 40
leading to the formation of advanced plaques was primarily caused
by lipid loading of foam cells already present at 30 weeks (clusters
1 and 3 in Figure 2A–2C). We suspected that some of the
cholesterol-responsive genes identified at 30 weeks (Table S12)
were essential to this process. To address this, total RNA was
isolated from targeted and control THP-1 macrophages in cell
culture that had been activated by PMA, treated with siRNA or
mock and then incubated with acetylated-LDL (AcLDL) for
48 hours (see also Methods and Text S1). Expression data
(Affymetrix Hu 130, 2.0+) was generated from 12 siRNA
experiments and 4 pools of controls treated with unspecific siRNA
(mock). Three transcripts, GPR120 (Entrez Gene ID 338557),
GPR81 (Entrez Gene ID 27198) and SOX6 (Entrez Gene ID
55553), were below the detection limits of the GeneChips
suggesting that these genes were not active enough in this
experimental model of foam cell formation to be detected or
inactive. The remaining genes were organized in a 9-by-9 data
matrix. Expression data for each gene was normalized by dividing
with the mean expression level in controls followed by log-
transformation. A linear gene regulation model
dxi
dt
~
X n
j~1
wijxjzpi
was fit to data as previously described [9]. Here x denotes
expression data vectors, W is the network adjacency matrix, and p
is the perturbation vector. In each knockdown experiment, the
elements of p were 21 for the perturbed gene and 0 for all other
genes. Note that because of the log-transform, this corresponds to
a multiplicative model in actual expression levels. The algorithm
controls the trade off between precision and recall by a single
parameter d. In our experiments we chose d=0.2. In simulations
we found that this value corresponds to approx. 60% precision and
80% recall. Of note, interactions between genes (i.e. directed edges
with stimulating or repressing effect) do not imply direct biological
interactions but in most instances indirect (for instances mediated
by proteins, metabolites or even intermediate genes (with low
expression level such as transcription factors)).
PRKAR2B (Entrez Gene ID 5577) had no edges to the other
nodes (e.g. genes). The remaining eight nodes were found to
belong to a regulatory gene network (Figure 4A, Table 2). These
nodes included CD36 (Entrez Gene ID 948), which previously has
been shown to promote foam-cell formation [10], and PPARA
(Entrez Gene ID 5465) [11], which previously has been shown to
prevent it [11]. Hydroxysteroid dehydrogenase-like 2 (HSDL2,
Entrez Gene ID 84263) up-regulated PPARA and down-regulated
CD36. Moreover, poliovirus receptor-related 2 (PVRL2, Entrez
Gene ID 5819) also regulated CD36, increasing its expression and
negatively regulating HSDL2 and thus indirectly suppressing
PPARA activity. From the regulation of CD36 and PPARA in this
regulatory network (Figure 4A), it can be predicted that inhibiting
PVRL2 would prevent foam-cell formation and inhibiting HSDL2
would promote it. To validate the network, we tested these
predictions by assessing the effect of inhibiting individual genes
within the network on cholesterol-ester (CE) and lipid accumula-
tion. The CE accumulations in the THP-1 cells in response to
siRNA treatments were in agreement with our predictions
(Figure 4A, Table 3). siRNA treatment against several of the
other network nodes also affected CE accumulation in THP-1
macrophages (Figure 4A). Representative microscopic images of
siRNA treated macrophages stained wit Oil-red-O are shown in
Figure 4B.
Discussion
In this study, we first used genome-wide expression profiling to
identify a point before which atherosclerosis developed slowly and
only low-level inflammation was present. After this point, lesions
expanded rapidly and inflammation increased markedly. The
inflammation persisted in late phases, leading to the formation of
advanced plaques, but lesion size increased transiently during a
10-week period. The rapid lesion expansion was primarily caused
by an equally rapid lipid accumulation in macrophages. In early
lesions, macrophages with low degree of inflammation and low
lipid content accumulated. At a certain point, this accumulation
halted and was followed by a rapid increase in macrophage lipid
content paralleled by an induction of inflammatory genes.
Lowering plasma cholesterol at this point prevented the rapid
expansion of the lesions and the formation of advanced plaques.
Table 1. Plasma cholesterol, triglyceride, and glucose concentrations of representative Ldlr
2/2Apob
100/100Mttp
flox/floxMx1-Cre mice.
Plasma level (mg/dl) Age (weeks)
10.660.4 (n=7) 21.361.1 (n=5) 29.660.0 (n=6) 40.360.0 (n=5) 50.560.8 (n=5) 61.060.0 (n=4)
Cholesterol 361.2664.2 345.7665.3 427.0672.4 461.9614.1 427.2674.2 527.3671.5
Triglycerides 83.0625.8 84.1610.5 87.8617.0 84.7620.0 108.6626.2 89.6638.3
Glucose 359.6650.6 425.4676.2 369.8637.8 311.4628.5 350.6619.6 376.0638.3
Values are mean 6SD. There were no statistically significant differences between time points (P.0.05).
doi:10.1371/journal.pgen.1000036.t001
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responsive atherosclerosis genes. Validation of the macrophage-
related part of these genes by additional transcriptional profiling of
mRNA from siRNA-targeted THP1—macrophages incubated
with AcLDL exposed a regulatory gene network of foam-cell
formation. This network as a whole and some of its individual
nodes (particularly PVRL2 and HSDL2) should be considered for
therapies to prevent the formation of advanced plaques.
Transcriptional profiles of atherosclerosis lesions are challenging to
interpret [3]. Such lesions contains several cell types, and the average
mRNA contribution of a given cell type is altered with disease
development. Thus, changes in mRNA levels represent a mixture of
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Figure 2. Transcriptional changes of atherosclerosis development. (A) Heat map of clustered mRNA levels (rows; red, high levels; blue, low
levels) for genes differentially expressed (d.e.) in at least one pair-wise time-point comparison (FDR,0.05, n=1259). Each column represents mRNA
levels in one mouse (n=5 to 7 per time point) at 10 to 60 weeks of age. Four gene clusters were identified by the cluster algorithm. Pie charts show
percentages of genes related to atherosclerosis (Table S1) on the left and to the four atherosclerosis cell types (Tables S2, S3, S4, and S5) on the right.
A substantial number of genes were related to more than one atherosclerosis cell type (Figure S1). The percentage of novel genes (i.e., not related to
atherosclerosis or atherosclerosis cell types) in each cluster is shown on the far right. Overall percentages (total) are shown below. (B) Relative
expression levels of cell-specific markers of atherosclerosis cell types (Table S7). The number of markers per cell type is indicated. The only statistically
significant increase was in the number of foam cells, which increased by ,30% between 20 and 30 weeks (P,0.001) and remained elevated at
60 weeks. (C) Representative sections of the aortic root (top) were stained with Oil-red-O (red in the figure) and counterstained with hematoxylin
(Htx) (blue spots in the figure), bar in figure indicate 50 mm; higher-power views of 50 mm showing foam cells at 30 (arrows indicate macrophage Htx-
stained nuclei, asterisk marked arrows point to the outer cell membrane) and 40 weeks (asterisk marked arrows point to the outer cell membrane of
Oil-red-O-stained fat within macrophages, the nuclei are not visible) are shown below.
doi:10.1371/journal.pgen.1000036.g002
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PLoS Genetics | www.plosgenetics.org 5 2008 | Volume 4 | Issue 3 | e1000036actual changes in cellular mRNA concentrations and changes in cell
type admixture. In addition, cells in different stages of proliferation
and differentiation (e.g., macrophages differentiation into foam cells)
adds to this problem also within a given cell type. However, the
current lesion mRNA dataset over tight time intervals provides, to
our best knowledge, the most comprehensive compendium of lesion
expression profiles representing known and novel biological processes
and pathways activated during atherogenesis (Figure 2A).
Analysis of lesion mRNA clusters (Figure 2A) indicated that, at
first, macrophages infiltrate the arterial wall, leading to the
formation of fatty streaks. Then, at what appears to be a rather
specific time point, these cells become activated, leading to a burst
of inflammatory activity that, in combination with a rapid
accumulation of CE in macrophages, generates advanced plaques;
documented as a critical step in atherogenesis [12]. We believe this
transformation can be related to the density of macrophages in the
arterial wall. At a given density, the macrophages not only
stimulate themselves (autocrine) but also stimulate each other
(paracrine), leading to a burst of inflammatory activities and
increasing lipid uptake. If such a mechanism is also present in
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Figure 3. Effect of plasma-cholesterol lowering on lesion progression. Lesion surface area was determined as the percentage of lesion area
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cholesterol control mice were injected with PBS. (A) At 40 weeks of age, lesion surface area in mice with low plasma cholesterol (i.e., pI-pC-treated,
n=7) had not progressed and differed significantly from that in high-cholesterol controls at 40 weeks (i.e., PBS-treated, n=6) (*P,0.005). Figure 1A is
shown for comparison; red line indicates mice with low plasma cholesterol. (B–D) One week of low levels of cholesterol (30-week-old mice) did not
affect lesion size (P=0.96), (B) Shown are percent relative changes in lesion area. Figure 1A is shown for comparison; red line indicates the low-
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lesions.
doi:10.1371/journal.pgen.1000036.g003
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Figure 4. A regulatory gene network of foam-cell formation. Twelve cholesterol-responsive atherosclerosis genes (Table S12, in bold) were
targeted in THP-1 macrophages using siRNA. Two days after transfection, siRNA-targeted macrophages and controls treated with nonspecific siRNA
were incubated with AcLDL (50 mg/mL) for 48 hours; total RNA was isolated, and CE and lipid accumulation were determined. (A) Sixteen expression
profiles (HG-U133_Plus_2 arrays, Affymetrix) from 12 siRNA experiments and four pooled controls were used to generate the regulatory gene
network (Results) of 8 cholesterol-responsive genes involved in foam-cell formation, including PPARA and CD36. CE accumulation (given as average
percentage next to each node) was decreased (blue) by siRNA inhibition of 5 genes and increased (red) by inhibition of 2 genes; inhibition of 1 gene
had no effect (black) (see also Table 3). (B) Representative siRNA treated THP-1 cells after 48 incubation with AcLDL and stained with Oil-red-O.
doi:10.1371/journal.pgen.1000036.g004
Table 2. siRNA inhibition of eight cholesterol-responsive network genes in THP-1 macrophages incubated with acetylated LDL.
Gene symbol
Control (relative mRNA
levels)
siRNA knock (relative
mRNA levels) P-value
siRNA inhibition (%
relative control) siRNA assay ID
a
AGL 1.0460.09 0.3760.17 ,0.001 64 110579
AGPAT3 1.0060.09 0.3160.04 ,0.001 69 112079
CD36 1.0260.12 0.3560.02 ,0.001 66 105939
GYPC 1.0060.09 0.4860.11 ,0.001 52 11041
HSDL2 1.4160.13 0.3660.03 ,0.001 74 33815
HMGB3 1.1060.05 0.3860.04 ,0.001 65 145247
PPARA 1.1960.20 0.3760.05 ,0.001 69 291496
PVRL2 1.2660.16 0.4460.03 ,0.001 65 12251
asiRNA assays purchased from Ambion.
doi:10.1371/journal.pgen.1000036.t002
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development may be very important. Indeed, in these mice, the
formation of advanced plaques was all together prevented by
genetic lowering of plasma cholesterol immediately before the
rapid lesion expansion (Figure 3A).
In contrast to mRNA profiles isolated during lesion develop-
ment, the extent and relative composition of different cell types in
the lesions were similar before and after the subacute lowering of
plasma cholesterol (Figure 3B–3D). Thus, in this case the changes
in mRNA concentration monitored by the GeneChips reflect
actual changes in cellular mRNA levels. Since the accumulation of
lipids in macrophages was a central process in the rapid lesion
expansion and formation of advance plaques (clusters 1 and 3 in
Figure 2A–2C), we used siRNA in THP-1 macrophages incubated
with AcLDL to validate the cholesterol-responsive genes (Table
S12). Eight genes were found to belong to a regulatory gene
network in which PVRL2 and HSDL2 had central roles. Little is
known about PVRL2 and HSDL2 (generating 6 and 3 hits in
PubMed, respectively). A sequence variant in PVRL2 is associated
with the severity of multiple sclerosis [13]. HSDL encodes the
sterol carrier protein-2, a small intracellular basic protein domain
that enhances the transfer of lipids between membranes in vitro
[14].
Although pointing out isolated candidates as being more
promising than others is tempting, the lesson from whole-genome
approaches will most certainly be that complex diseases like
atherosclerosis will not be defeated by targeting single genes
(probably not even single regulatory genes) but instead to target
several genes belonging to a similar network of pathology [9,15].
This notion is supported by studying a small gene network as the
present (Figure 4A) where none of the nodes (i.e., genes) can be
said to solely promote or inhibit foam-cell formation.
Our findings imply that the timing of interventions with plasma
cholesterol-lowering agents may be very critical. Patients at risk of
developing complications of atherosclerosis (e.g., stroke and MI)
may benefit from being treated very early in life. The
development of noninvasive technologies to detect early athero-
sclerosis or molecular markers of atherosclerosis stages will be
important in this respect. For normo-cholesterolemic individuals
but with other atherosclerosis risk factors, novel regimens
targeting atherosclerosis genes that mediate the beneficial effects
of plasma cholesterol-lowering may be useful. In summary, the
network of cholesterol-responsive atherosclerosis target genes and
regulators of foam-cell formation identified in our study merits
further attention.
Materials and Methods
The Mouse Model
The Ldlr
2/2Apob
100/100Mttp
flox/floxMx1-Cre mouse model has a
plasma lipoprotein profile similar to that of familial hypercholes-
terolemia, which causes rapid progression of atherosclerosis [7].
For Mttp deletion, mice were injected with 500 ml of pI-pC (1 mg/
ml; Sigma, St. Louis, MO) every other day for 6 days to induce Cre
expression, thereby recombining Mttp (Mttp
D/D) or not in the
Ldlr
2/2Apob
100/100Mttp
wt/wt Mx1-Cre mice. Littermate controls
received PBS (Mttp
flox/flox). The study mice had been back crossed
5 times to C57BL/6 (,5% 129/SvJae and .95% C57BL/6),
were housed in a pathogen-free barrier facility (12-hour light/
12-hour dark cycle), and were fed rodent chow containing 4% fat.
Genotypes were determined by polymerase chain reaction (PCR)
with genomic DNA from tail biopsies. Plasma cholesterol and
triglyceride concentrations were determined in non-fasted blood
samples with colorimetric assays (Infinity cholesterol/triglyceride
kits; Thermo Electron, Melbourne, Australia), and plasma glucose
levels with Precision Xtra (MediScience, Cherry Hill, NJ).
En Face Analysis and Histology
Aortas were pinned out flat on black wax surfaces as described
[16], stained with Sudan IV, photographed with a Nikon
SMZ1000 microscope, and analyzed with Easy Image Analysis
2000 software (Tekno Optik, Ska ¨rholmen, Sweden). Lesion area
was calculated as a percentage of the entire aortic surface between
the aortic root and the iliac bifurcation. Aortic roots were isolated
and immediately frozen in liquid nitrogen in OCT compound
(Histolab, Va ¨stra Fro ¨lunda, Sweden). Cryosections (20 mm) were
cut and stained with hematoxylin (Htx) and Oil-red-O as
described [17]; other sections (6–8 mm) were incubated first with
rat anti-mouse CD68 antibody or a control antibody (Serotec,
Oxford, England) overnight at 4uC and then with fluorescent anti-
rat IgG (Vector Laboratories, Burlingame, CA) and counter-
stained with mounting medium containing DAPI (Vector
Laboratories).
Transcriptional Profiling
Aortas were perfused with RNAlater (Qiagen, Valencia, CA),
and the aortic arch from above the third rib to the aortic root
was removed and homogenized with FastPrep (Qbiogene, Irvine,
CA). Total RNA was isolated with RNeasy Mini Kit (Qiagen)
using a DNAse I treatment step. RNA quality was assessed with
a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA).
Table 3. Effects of siRNA inhibition of eight cholesterol-responsive network genes on cholesterol-ester accumulation in THP-1
macrophages incubated with acetylated LDL.
Gene symbol Control (relative CE levels) siRNA knock (relative CE levels) P-value CE content (% relative control) Oil-Red-O staining
AGL 100615 62622 ,0.001 237 decreased
AGPAT3 98617 85617 ns 214 decreased
CD36 89626 7 62 ,0.001 225 decreased
GYPC 100634 99652 ns nd -
HSDL2 100615 177610 ,0.001 +77 increased
HMGB3 97610 70620 ns 228 decreased
PPARA 126651 5 0 613 ,0.05 +19 increased
PVRL2 100687 0 613 0.002 230 decreased
CE, cholesterol ester; nd, no difference; ns, not significant.
doi:10.1371/journal.pgen.1000036.t003
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flox/flox, 5 from Mttp
D/D,
and 9 Mttp
wt/wt mice) were used for global gene expression
measurements with cDNA arrays (Mouse Genome 430 2.0
GeneChips, Affymetrix, Santa Clara, CA) at 10 (n=7, PBS), 20
(n=5, PBS), 30 (n=6, PBS+5, pI-pC), 40 (n=5), 50 (n=5), and
60 (n=4) weeks. In addition at 30 weeks, 9 Mttp
wt/wt (n=5,
PBS+4, pI-pC). All samples were prepared with the two-cycle
protocol recommended by the manufacturer. Arrays were scanned
with GeneChip Scanner 3000 and analyzed with GeneChip
Operating Software (Affymetrix).
Text Mining and Prior Atherosclerosis Knowledge
Automated text mining of PubMed was used to establish lists of
genes related to atherosclerosis, foam cells, smooth muscle cells,
endothelial cells, and T cells. Briefly, a gene was considered related
if it co-occurred with any of the following terms in the abstract of
an article in PubMed: atherosclerosis, arteriosclerosis (‘‘atherosclerosis-
related’’, Table S1), foam cell, macrophage, monocyte (‘‘foam cell
related’’, Table S2), smooth muscle cell (Table S3), endothelial cell
(Table S4), and T-cell (Table S5). These tables constitute fairly
comprehensive but not specific lists of genes with possible roles in
atherosclerosis or in the cell types involved in atherosclerosis (i.e.,
may contain false positives but a low number of false negatives)
with a substantial overlap (Figure S1). We also generated a list of
‘‘established’’ atherosclerosis genes by manually extracting from
recent reviews genes known to be important in atherosclerosis
(Table S6).
siRNA of THP-1 Macrophages Incubated with Acetylated-
LDL
Monocytes of the human monocytic cell line THP-1 were
plated in six-well culture dishes (Becton Dickinson Labware, NJ)
at 6 610
5 cells/well in 10% fetal calf serum (FCS)-RPMI-1640
medium with L-glutamine (2 mM) and HEPES buffer (25 mM)
(Gibco-Invitrogen, Carlsbad, CA) supplemented with penicillin
(100 U/mL) and streptomycin (100 mg/mL) (PEST) and induced
to differentiate into macrophages with phorbol 12-myristate 13-
acetate (PMA) (50 ng/mL) (Sigma) for 72 hours. For each gene,
cells were transfected with up to three siRNAs (Ambion, Austin,
TX), using Lipofectamine 2000 according to the manufacturer’s
instructions (Invitrogen), in medium without FCS, PEST, and
PMA. Two days after transfection, siRNA-targeted macrophages
and mock-treated controls (nonspecific siRNA) were incubated
with AcLDL (50 mg/mL) for 48 hours in 1% FCS medium with
PEST. AcLDL was prepared as described [18]. The samples
were dialyzed against PBS at 4uC. AcLDL protein concentration
was determined by the Bradford method. LDL was isolated from
the plasma of healthy donors by sequential ultracentrifugation
[19].
Lipid, Protein, and Gene Expression Measurements
For lipid imaging, THP-1-derived foam cells were fixed with
10% formaldehyde in PBS for 10 min and washed twice with PBS.
The cells were stained with Oil-red-O (0.3% in 60% isopropanol)
for 20 min, washed twice with 60% isopropanol and twice with
PBS, and examined with a Nikon Eclipse E800 microscope at 406
magnification. Lipids were isolated by hexan/isopropanol (3:2)
extraction at room temperature for 1 hour followed by 0.5 ml
chloroform for 15 min [20]. The lipid extracts were dried and
resuspended in 80 ml of isopropanol with 1% Triton-X-100
(Sigma). The lipid content of the foam cells was determined by
enzymatic assays using the Infinity kit for total cholesterol
(Thermo Electron) and a kit for free cholesterol (Wako Chemicals,
Richmond, VA). After lipid extraction, proteins were extracted
from the same wells by incubation with 0.5 M sodium hydroxide
for 5 hours at 37uC. Protein concentration was determined by the
Bradford method.
For HG-U133_Plus_2 array analysis (Affymetrix) and to
determine the degree of knockdown by siRNA, total RNA was
isolated from the AcLDL-incubated THP-1 cells with RNeasy
Mini-kit (Qiagen). The concentration was determined with a
spectrophotometer (ND-100, NanoDrop Technologies, Wilming-
ton, DE). For cDNA synthesis, 0.5 mg of total RNA was reverse
transcribed with Superscript II (Invitrogen) according to the
manufacturer’s protocol. After 5-fold dilution, cDNA (3 mL) was
amplified by real-time PCR with 16TaqMan universal PCR
master mix (Applied Biosystems, Foster City, CA) on an ABI
Prism 7000 (PE Biosystems) and software according to the
manufacturer’s protocol. Assay-On-Demand Kits containing
corresponding primers and probes from Applied Biosystems were
used, and expression values were normalized to acidic ribosomal
phosphoprotein P0. Each sample was analyzed in duplicate (Text
S1).
Statistics and Calculations
Differences in the mRNA levels of selected genes, mouse plasma
measurements, and lesion surface areas between time points were
analyzed with unpaired t tests. Gene expression signal-level data
were computed with MAS 5.0 (Affymetrix) using default settings,
log-transformed, and normalized to total intensities (global
scaling). After normalization, signal intensities were computed
for each gene in the Mouse Genome Informatics Database (MGD
genes, Jackson Laboratory, www.jax.org) by averaging the signal
of the corresponding Affymetrix probe sets. Of the 11,979
GeneChip probe sets (Mouse Genome 430 2.0 GeneChips,
Affymetrix) that had no match in the database, 1.5% were
differentially expressed (false discover rate (FDR) ,0.05, n=177),
representing the fraction of genes/probe sets that were not
considered for further analyses. The remaining 33,122 probe sets
had at least one match in 19,879 MGD genes (of a total of 32,095).
Lowess normalization [21] was applied in pair-wise fashion before
differential expression testing. To correct for multiple testing when
computing probabilities of differential expression and FDRs, we
used empirical Bayes statistics [8]. Clustering was performed with
the FindCluster algorithm in Mathematica 5.1 (Wolfram Re-
search, Champaign, IL). GO and pathway analyses were
performed with EASE software [22]. The regulatory gene network
of THP-1 macrophages incubated with AcLDL was inferred as
described [9].
Supporting Information
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Tables S2, S3, S4, and S5
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2
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XLS)
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